SPAC

A SPAC (Special Purpose Acquisition Company) is an alternative way of raising capital through an initial public offering, before acquiring an operating target company.
SPAC

A SPAC (Special Purpose Acquisition Company) is an alternative way of raising capital through an initial public offering (IPO), before acquiring an operating target company. SPAC management teams usually target a broader industry or sector rather than a specific company. Once the SPAC goes public, it has a set timeframe – typically 24 months – to use the funds that it has raised to acquire a target. If it does not make an acquisition (“de-SPAC”), it will return its funds to the investors.

SPAC activity has undergone a significant uptick recently. A SPAC not only poses an attractive opportunity for investors, it also offers companies greater control over their valuation and share price – unlike a traditional IPO with its inherent market volatility risks.

Houthoff’s ECM team was the first in the Netherlands to assist with the launch of a Dutch SPAC, using an anti-takeover construction (European Healthcare Acquisition & Growth BV).

Capital Markets
Whether you want to raise capital through equity, debt or alternative forms of financing, you need to thoroughly understand the sector and the legal ins and outs of domestic and international capital market regulations.
Corporate/M&A
Mergers and acquisitions are among the most transformative decisions a business can make – whether driven by ambitions for growth, entry into new markets, evolving industry dynamics or long-term investment objectives. These transactions demand clear insight and the ability to navigate legal and regulatory complexity across jurisdictions.

Recent
work

Advised European Healthcare Acquisition Growth Company B.V., a Euronext Amsterdam-listed special purpose acquisition company (SPAC), on the intended business combination with Croma-Pharma GmbH.

Advised Frazier Lifesciences Acquisition Corporation (SPAC) on its intended business combination with NewAmsterdam Pharma and listing of the combined entity on Nasdaq.

Advised Ally Bridge Group on its €30 million PIPE investment in the business combination between BenevolentAI, a UK-based leading clinical-stage AI drug discovery company, and Odyssey Acquisition SA, a SPAC listed on Euronext Amsterdam. With this business combination, BenevolentAI is valued at €1.1 billion (pre-money) and €1.5 billion (post-money).

Advised European Healthcare Acquisition Growth Company B.V., a Euronext Amsterdam-listed special purpose acquisition company (SPAC), on the intended business combination with Croma-Pharma GmbH.

Advised Frazier Lifesciences Acquisition Corporation (SPAC) on its intended business combination with NewAmsterdam Pharma and listing of the combined entity on Nasdaq.

Advised Ally Bridge Group on its €30 million PIPE investment in the business combination between BenevolentAI, a UK-based leading clinical-stage AI drug discovery company, and Odyssey Acquisition SA, a SPAC listed on Euronext Amsterdam. With this business combination, BenevolentAI is valued at €1.1 billion (pre-money) and €1.5 billion (post-money).

Publications

26 December 2022
26 December 2022
Een tweegesprek over de ontwikkelingen op het gebied van de SPAC. MenA.nl.
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.